Home
-
CDMOs/CMOs: The Movers and Shakers of 2025
As 2025 comes to a close, what were the key developments—expansions and M&A—from CDMOs/CMOs this year? DCAT Value Chain Insights looks at the companies and moves that topped the headlines this year.
-
EU Policymakers Take Next Step in Key Pharma Reforms
The European Commission, the European Parliament, and the Council of the European Union, have agreed to a proposal for the EU’s landmark pharma legislation, setting the stage for major reforms.
-
2025: The Bio/Pharma Industry’s Year in Review
Without question, US-imposed tariffs and ensuing trade deals and the impact on the bio/pharma industry was the number one news story in 2025, going hand-in-hand with US manufacturing investments and drug pricing reforms. What else made the news?
DCAT MEMBER COMPANY COMMUNITY
-
New Episode: Production to Prescription Podcast: 2025: The Bio/Pharma Industry’s Year in Review
Without question, evolving US tariff and trade policy was the story of the year in 2025, and how such policy will be implemented looms large. At the same time, the…
-
ICYMI: 2026 DCAT Value Chain Insights Editorial Calendar Now Available
In case you missed it, the 2026 DCAT Value Chain Insights Editorial Calendar is now available. The feature schedule for 2026 focuses on major themes impacting the business of bio/pharmaceutical…
-
New DCAT Member Company Alert
Welcome to the newest Member Companies in the Drug, Chemical & Associated Technologies Association (DCAT). DCAT is pleased to welcome the following companies to the DCAT Member Community. To view…
-
ESG Update: DCAT Member Companies in the Community
The latest ESG (environmental, social and governance) news from DCAT Member Companies on how they are making an impact globally and in their local communities. Have a ESG news announcement…
